TB Alliance
- Company typePrivate
- Founded2000
- HeadquartersNew York, United States
- Headcount11–50
- GTM typeB2B
- OfferingHardware or Manufacturing
TB Alliance firmographics
Firmographics- Name
- TB Alliance
- Legal name
- Global Alliance for TB Drug Development Inc.
- Website
- https://tballiance.org
- Company type
- Private
- Founded year
- 2000
- Operating status
- Operating
- Headcount range
- 11–50 employees
- Ownership category
- akta.pro rank
TB Alliance industry classification
Industry- Product category
- Tuberculosis Drug Development
- NAICS
- Research and Development in Biotechnology (except Nanobiotechnology) (541714), Professional Organizations (81392)
- SIC
- Pharmaceutical Preparations (2834), Services-Commercial Physical & Biological Research (8731)
- akta.pro primary industry
- Global Health Research, Clinical Trials & Product Development Partnerships (PDPs) (HLAJAOAM)
- akta.pro secondary industries
- Disease-Specific Global Initiatives (HIV/TB/Malaria/NTDs) (HLAJAOAE), Tuberculosis & Mycobacterial Diseases (HLAKAGAH)
Keywords
Where TB Alliance is headquartered
LocationHeadquarters
- HQ city
- New York
- HQ country
- United States
- HQ region
- North America
Offices2 records
Markets served
TB Alliance business model
Business model- GTM type
- B2B
- Offering type
- Hardware or Manufacturing
- Cost components
- Technology or R&D, Personnel, Operations, Marketing or Sales, Supply Chain
Revenue model
- Not-for-profit / Mission-driven organization: TB Alliance is a not-for-profit Product Development Partnership (PDP) that does not generate revenue through traditional commercial means. The organization is funded by governments, foundations, and institutional donors to discover, develop and deliver TB drugs. As a not-for-profit, TB Alliance makes the products it develops available to those who need them through partnerships and access initiatives rather than commercial sales.
Pricing tiers
| Model | Billing | Price |
|---|---|---|
| Unit Pricing | Multi-year contract | BPaL/M regimen treatment cost |
Go-to-market motion1 record
Distribution channels5 records
Marketing channels10 records
TB Alliance product offering
Product offeringCore offering
TB Alliance is a not-for-profit product development partnership that discovers, develops, and delivers new tuberculosis drug regimens. Its offerings include novel chemical entities (e.g., pretomanid), combination regimens (BPaL, BPaL/M, SPaL), pediatric fixed-dose combinations, and long-acting injectable formulations, made available at affordable not-for-profit pricing through manufacturer licensees and global procurement institutions. The organization also operates market access programs (LIFT-TB, PeerLINC, Fast Track the Cure) and digital tools (Upskill TB, Manage TB) to accelerate country adoption.
Product overview
TB Alliance operates as a not-for-profit product development partnership managing the largest pipeline of new TB drugs in history. Its portfolio spans Discovery (lead identification/optimization programs including Malate Synthetase Inhibitors, ClpC1, MmpL3 Inhibitors, RNA Polymerase Inhibitors), Clinical Development (Phase 1-4 trials including TBAJ-587, NC-009/SPaL, Telacebec/Q203), and Marketed Products (Pretomanid, BPaL/BPaL/M regimens, pediatric formulations). Beyond TB, TB Alliance develops treatments for related mycobacterial diseases including leprosy and Buruli ulcer. Access initiatives include LIFT-TB, PeerLINC Knowledge Hub, Fast Track the Cure, SLASH-TB, and digital tools like Upskill TB and Manage TB to accelerate global adoption of new TB treatments.
Differentiator
Problem solved
Functional benefit
Products and services
- Pretomanid Pretomanid is a new chemical entity (nitroimidazooxazine) developed by TB Alliance for treating drug-resistant tuberculosis in combination regimens. Approved by US FDA (2019), EU (2021), India DCGI (2020), and prequalified by WHO (2021). It is made available to governments and global health programs at affordable not-for-profit pricing.
- BPaL Regimen BPaL is a three-drug, all-oral, six-month regimen consisting of bedaquiline + pretomanid + linezolid for treating highly drug-resistant TB. FDA-approved for XDR-TB and treatment-intolerant MDR-TB with approximately 90% treatment success rates in clinical trials and real-world implementation.
- BPaL/M Regimen BPaL/M is a modified BPaL regimen with moxifloxacin for treating multiple forms of drug-resistant TB. Currently used in over 100 countries, saving lives and reducing healthcare costs, with treatment success rates above 90% in real-world implementation.
- SPaL Regimen (Sorfequiline + Pretomanid + Linezolid) Novel regimen featuring sorfequiline (TBAJ-876), a next-generation diarylquinoline, combined with pretomanid and linezolid. Phase 2 trial showed greater efficacy than standard treatment with potential to shorten TB therapy. Subsequent plans include Phase 3 trial and long-acting injectable development.
- Telacebec (Q203) Investigational drug being developed for treating multiple mycobacterial diseases including tuberculosis, leprosy, and Buruli ulcer. Phase 2 trial underway. Under collaboration with Novartis (for leprosy) and Lupin (for clinical development and commercialisation).
- TBAJ-587 Diarylquinoline compound in Phase 1 clinical trials. Lead candidate for long-acting injectable formulations demonstrating sustained systemic exposure for up to four months in animal models.
- Pediatric TB Medicines Child-friendly TB treatments in correct fixed-dose combinations of rifampicin, isoniazid, and pyrazinamide with palatable fruit flavors that quickly disperse in liquid. WHO prequalified and ordered by 137 countries, covering 99% of global pediatric TB notifications; nearly 3 million treatment courses delivered.
- Long-Acting Injectable TB Formulations Long-acting injectable formulations for TB drugs designed to maintain therapeutic drug levels for months from a single injection, potentially enabling one-shot cures for active and latent TB. Lead candidates include sorfequiline, pretomanid, and TBAJ-587.
Quantifiable outcome
- 2+ million people treated with BPaL/M in first 15 years following approval
- +8 more outcomes
Companies that use TB Alliance
Customer profileNamed customers3 records
Segments4 records
Ideal customer profiles3 records
TB Alliance technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Feature6 records
TB Alliance partnerships and signals
Strategic signalPartnerships
18 partnerships are on record, tiered core and major.
- LupincoreLupin partnered with TB Alliance for clinical development and commercialisation of investigational drug Telacebec (Q203) for treating multiple mycobacterial diseases including tuberculosis, leprosy, and Buruli ulcer. TB Alliance leads development process while Lupin supports global manufacturing, regulatory affairs, and supply chain operations to ensure global access.
- NovartiscoreNovartis and WHO renewed partnership to provide multidrug therapy for leprosy globally at no cost for another five years, with goal to treat one million more people by 2030. Additionally, Novartis announced collaboration with TB Alliance to develop potential next-generation leprosy treatment - the first innovation in the disease since multidrug therapy was introduced over 40 years ago. TB Alliance to provide scientific and strategic advice on development.
- Indonesian Ministry of HealthcoreTB Alliance forged strategic partnership with Indonesian Ministry of Health in 2025 to advance treatment innovation in TB and other mycobacterial diseases.
- Fiocruz (Oswaldo Cruz Foundation)corePartnership with Fiocruz (through Farmanguinhos) to accelerate access to new and next-generation TB treatments.
- Asian Development BankcoreStrategic partnership to strengthen health systems, expand access to quality TB care, and promote coordinated innovation to accelerate progress toward TB control and elimination.
- Johns Hopkins UniversitycoreCollaborated on modeling exercise quantifying BPaL/M impact. JHU conducted research showing regimen will save 191k lives and $1.29B by 2034. Partnership for preclinical screening of potential drug combinations using predictive animal models.
- ViatriscoreManufacturing partner for pretomanid and TB Alliance products. Works to ensure consistent global supply of products at affordable prices.
- MacleodscoreManufacturing partner for pretomanid and child-friendly TB formulations. Helps ensure consistent global supply at affordable prices.
- Hongqi PharmaceuticalcoreManufacturing partner for TB Alliance products to ensure consistent global supply at affordable prices.
- Remington PharmaceuticalscoreManufacturing partner for TB Alliance products in Pakistan to ensure regional supply access.
- Stop TB Partnership Global Drug FacilitycoreGlobal procurement institution facilitating access to TB medicines. TB Alliance works with GDF to ensure countries can access new treatments.
- The Global FundcoreGlobal health financing institution supporting TB programs. Works with TB Alliance to ensure affordable access to new TB treatments through funding and procurement.
- World Health Organization (WHO)coreWHO provides normative guidance, treatment guidelines, and prequalification for TB Alliance products. Updated guidelines in 2022 to allow programmatic implementation of treating DR-TB with pretomanid-containing regimens. Recognized BPaL/M rollout as example of effective new antibiotic introduction.
- Afrigen Biologics and VaccinescoreJoined TB Alliance's Global TB Stakeholders as partner in mRNA technology and LMIC capacity strengthening initiatives.
- Desmond Tutu TB CentrecoreJoined TB Alliance's Global TB Stakeholders. Partnership focuses on championing children in the fight against TB.
- Clinton Health Access InitiativemajorGlobal health organization and TB Alliance partner for access initiatives. Rasha Hibri, former CFO, serves on TB Alliance Board.
- LIFT-TB PartnerscoreLIFT-TB (Leveraging Innovation for Faster Treatment of Tuberculosis) initiative in partnership with International Tuberculosis Research Center, South Korea and KOICA. Supported introduction of BPaL/M across seven countries: Indonesia, Kyrgyzstan, Myanmar, Philippines, Ukraine, Uzbekistan, Vietnam.
- Fast Track the Cure PartnerscoreCommunity engagement initiative with partners including ASPAT Peru, CEDAPS (Brazil), Dopasi Foundation (Pakistan), Nari Maitree (Bangladesh), REACH (India), and TB Network (Nigeria). Mobilizing communities in nine high-burden countries to raise awareness and facilitate access to new DR-TB treatments.
Scale indicators15 records
Recent moves2 records
TB Alliance competitors and assessment
Company assessmentDirect peers
- FIND (Foundation for Innovative New Diagnostics): FIND is a Geneva-based global health PDP accelerating the development and equitable access of diagnostic tests for poverty-related diseases including TB. It is closely comparable as a fellow global health product development partnership operating in the TB ecosystem with overlapping donors and partner network.
- PATH: PATH is a global nonprofit that advances equitable health innovation through cross-sector partnerships across vaccines, drugs, devices, and diagnostics. Shares the multi-disease global health product development mission, donor base, and access-driven delivery model used by TB Alliance.
- Medicines for Malaria Venture (MMV): MMV is a Swiss-based PDP specifically focused on discovering, developing, and delivering new antimalarial drugs—mirroring TB Alliance's mandate and PDP structure. Both organizations advance co-developed combination regimens through public-private partnerships and prioritize affordability/endemic-country access over commercial returns.
- International AIDS Vaccine Initiative (IAVI): IAVI is a nonprofit PDP focused on HIV vaccine and antibody R&D, sharing the same product development partnership model as TB Alliance and overlapping donor base (Gates, USAID, governments). It uses a similar distributed R&D approach, WHO prequalification pathway, and access-driven licensing strategy for global health products.
- Medicines Development for Global Health: An Australia-headquartered nonprofit pharmaceutical company that similarly develops, registers, and provides access to medicines for neglected diseases (moxidectin for river blindness). Shares the same 'not-for-profit developer' model, regulatory strategy, and focus on underserved populations that TB Alliance uses for tuberculosis.
- Drugs for Neglected Diseases initiative (DNDi): DNDi is the closest direct peer to TB Alliance—a not-for-profit Product Development Partnership that develops new treatments for neglected diseases (sleeping sickness, leishmaniasis, Chagas, pediatric HIV, hepatitis C, mycetoma) using the same PDP model with public/private partners and access-focused licensing. Both organizations share donor constituencies (Gates, Wellcome, MSF) and operate via distributed R&D networks with globally accessible pricing.
Others
- Clinton Health Access Initiative (CHAI): CHAI is a global health organization operating across HIV, TB, malaria, and other diseases that negotiates pricing, supplies medicines, and strengthens health systems in LMICs. CHAI works in a complementary, ecosystem-partner role with TB Alliance on access and pricing initiatives for pretomanid and BPaL/M regimens.
- Gavi, the Vaccine Alliance: Gavi is a public-private global health alliance accelerating equitable and sustainable access to vaccines in lower-income countries—an adjacent global health PDP-style organization. It co-funds and shapes the introduction of new products (potentially including TB vaccines under development) that affect the future demand for TB Alliance's drug regimens.
Market position
Strengths5 records
Weaknesses5 records
Competitive moat1 record
Key risks6 records
Key highlights7 records
Customer concentration
TB Alliance social profiles
Digital presenceTB Alliance compliance and trust
Trust signalCompliance4 records
TB Alliance financial estimates
Financial estimateRevenue estimate
Valuation estimate
TB Alliance leadership team
Management profileNumber of profiles
Profiles19 records
TB Alliance funding detail
Funding detailFunding overview
Funding rounds1 record
Investors1 record
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
TB Alliance M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about TB Alliance
What does TB Alliance do?
TB Alliance is a not-for-profit product development partnership that discovers, develops, and delivers new tuberculosis drug regimens. Its offerings include novel chemical entities (e.g., pretomanid), combination regimens (BPaL, BPaL/M, SPaL), pediatric fixed-dose combinations, and long-acting injectable formulations, made available at affordable not-for-profit pricing through manufacturer licensees and global procurement institutions. The organization also operates market access programs (LIFT-TB, PeerLINC, Fast Track the Cure) and digital tools (Upskill TB, Manage TB) to accelerate country adoption.
Is TB Alliance a public or private company?
TB Alliance is a private company. It is classified as nonprofit foundation owned and is currently operating.
When was TB Alliance founded?
TB Alliance was founded in 2000. It employs 11 to 50 people.
Where is TB Alliance based?
TB Alliance is headquartered in New York, United States, in the North America region.
How does TB Alliance make money?
One revenue line is on record: not-for-profit / Mission-driven organization.
Who are TB Alliance's main competitors?
Direct peers on record are FIND (Foundation for Innovative New Diagnostics), PATH, Medicines for Malaria Venture (MMV), International AIDS Vaccine Initiative (IAVI), Medicines Development for Global Health and Drugs for Neglected Diseases initiative (DNDi). Others are Clinton Health Access Initiative (CHAI) and Gavi, the Vaccine Alliance.
Does TB Alliance have an API?
No public API is recorded for TB Alliance.
What industry is TB Alliance in?
TB Alliance's product category is Tuberculosis Drug Development. Its primary akta.pro industry code is HLAJAOAM, Global Health Research, Clinical Trials & Product Development Partnerships (PDPs), with a secondary code of HLAJAOAE, Disease-Specific Global Initiatives (HIV/TB/Malaria/NTDs). Its NAICS code is 541714 and its SIC code is 2834.